The literature, one component at a time.

The short version

The KLOW research literature is four separate records, not one. Each component — KPV, GHK-Cu, BPC-157, TB-500 — was studied alone, mostly in cells and rodent models, and those records are presented here one component at a time. The blend itself has never been the subject of a controlled study.

A few important framing notes before the detail. KPV's strongest evidence is in gut inflammation models; GHK-Cu's is in dermal fibroblasts and topical wound contexts; BPC-157's is in rodent connective-tissue repair (the one group that dominates this literature is Sikiric and Seiwerth in Zagreb — independent replication outside that lab is comparatively sparse); and the TB-500 fragment's actin-binding data must be read against the full-length thymosin beta-4 literature from which it is derived, because most foundational efficacy data were generated with the native 43-amino-acid protein, not the seven-amino-acid fragment. The combination-evidence gap is surfaced as a primary callout throughout.

Component 01 — KPV

KPV is Lysine-Proline-Valine, the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH residues 11-13). Molecular weight 342.4 Da. In the canonical KLOW vial it occupies 10 mg of the 80 mg total (12.5 percent of vial mass).

The foundational anti-inflammatory study comes from Dalmasso and colleagues at the Veterans Affairs Medical Center in Atlanta. Working in human intestinal epithelial lines (Caco2-BBE, HT29-Cl.19A) and Jurkat T cells at 10 nM, they showed that KPV inhibits NF-κB and MAP-kinase signaling and reduces secretion of IL-8, IL-6, IL-12, TNF-α, and IFN-γ. In mice, oral KPV at 100 μM in drinking water reduced clinical, histological, and molecular markers of both DSS- and TNBS-induced colitis, with the PepT1 di/tripeptide transporter identified as the entry route ^[1].

Kannengiesser and colleagues independently confirmed anti-inflammatory activity in DSS colitis and CD45RBhi transfer colitis. In MC1R-deficient (MC1Re/e) mice, KPV rescued all animals from DSS mortality — strong evidence that the anti-inflammatory action is at least partially independent of the melanocortin receptors that mediate α-MSH's pigmentary effects ^[2].

Mechanistic work by Land at the University of Dundee dissected this further in human bronchial epithelial cells. KPV at 0.1-10 μg/mL dose-dependently suppressed NF-κB activation under TNF-α or respiratory syncytial virus stimulation. The peptide accumulated in cell nuclei and competitively blocked the p65RelA-importin-α3 interaction, preventing nuclear translocation of p65 ^[3].

KPV's reach beyond gut has grown since. A single 1 mg/kg intraperitoneal dose 30 minutes after controlled cortical impact in male C57Bl/6N mice reduced secondary lesion volume by about 24 percent, reduced cleaved-caspase-3-positive neurons, and shifted activated microglia toward a less inflammatory branched morphology ^[4]. A 2025 study in HaCaT keratinocytes showed that KPV at 50 μg/mL restored cell viability and inhibited PM10-induced pyroptosis by suppressing the ERK/p38 MAPK/NF-κB axis ^[6]. PepT1-targeted nanoparticle delivery (KPV co-assembled with the immunosuppressant FK506) significantly improved disease activity and restored tight-junction proteins in acute and chronic DSS colitis ^[5], and a 2025 systematic review identified KPV as a leading tripeptide candidate for inflammatory bowel disease pending controlled human trials ^[23].

Component 02 — GHK-Cu

GHK-Cu is the copper(II) complex of Glycyl-L-Histidyl-L-Lysine, also designated Copper Tripeptide-1 (CAS 49557-75-7). Molecular weight 340.39 Da. In the canonical KLOW vial it dominates the mass profile at 50 mg of the 80 mg total (62.5 percent).

The peptide was first isolated by Loren Pickart from human plasma in 1973, where its concentration is known to decline with age. The most-cited single dataset for its mechanism is the Pickart and Margolina 2018 review: at 1-10 nM in cultured human dermal fibroblasts, GHK-Cu altered expression of an estimated 4,192 human genes (about 31.2 percent of the protein-coding genome) by 50 percent or more, with 59 percent of affected genes upregulated and 41 percent downregulated. The strongest signal was on extracellular-matrix remodeling, antioxidant defense, anti-inflammatory pathways, and DNA repair ^[7].

Campbell and colleagues at Boston University extended the mechanism to damaged adult tissue. In cultured human lung fibroblasts from COPD patients, GHK at 10 nM reversed a gene-expression signature of emphysematous lung destruction, restored collagen I contractile function, and elevated integrin-β1 expression ^[8].

The 2025 Mao study placed GHK-Cu in the same colitis-model evidence space as KPV: oral gavage at 20 mg/kg daily for 14 days in male BALB/c mice reduced TNF-α, IL-6, and IL-1β, preserved colon length, and restored the tight-junction proteins ZO-1 and Occludin. Mechanistically, SIRT1 was upregulated, STAT3 phosphorylation suppressed, and the Th17/RORγt response dampened ^[9].

The topical-wound literature is robust. A GHK-Cu-loaded composite hydrogel closed full-thickness Staphylococcus aureus-infected wounds in male C57BL/6 mice at over 95 percent by day 12, versus about 65 percent in untreated controls, with hemostasis 3- to 4-fold improved and endothelial-cell migration enhanced (60.4 percent scratch closure versus 29.1 percent control) ^[10]. A separate 2025 review reported GHK-Cu conjugated with silver nanoparticles achieved 96 percent wound closure by day 11 against 22 percent in untreated controls ^[22].

Human data for GHK-Cu is almost entirely topical and cosmetic. The Leyden 67-women trial of a twice-daily GHK-Cu cream over 12 weeks significantly thickened the epidermis and dermis, stimulated keratinocyte proliferation, and outperformed both vitamin C and retinoic acid comparators on collagen deposition (70 percent versus 50 percent versus 40 percent of subjects) ^[11]. Systemic or injectable human trials are absent.

Component 03 — BPC-157

BPC-157 is Body Protection Compound 157, a synthetic 15-amino-acid peptide (sequence GEPPPGKPADDAGLV) derived from a fragment identified in human gastric juice. Molecular weight 1,419.5 Da. It originally entered clinical development as PL 14736 under Pliva and reached Phase 2 trials for inflammatory bowel disease before the program was not advanced. In the canonical KLOW vial it occupies 10 mg of the 80 mg total (12.5 percent).

Most BPC-157 evidence comes from the Sikiric / Seiwerth laboratory in Zagreb. Krivic and colleagues showed in 2006 that BPC-157 at 10 μg/kg intraperitoneally accelerated Achilles tendon-to-bone healing in rats, with substantial increases in Achilles functional index, load-to-failure, stiffness, and collagen organization, and partial offset of corticosteroid-induced healing impairment ^[12]. Cerovecki and colleagues then demonstrated medial collateral ligament healing improvements over 90 days after surgical transection, with consistent functional, biomechanical, and histological recovery across intraperitoneal, topical, and oral (drinking water) routes ^[13]. Novinscak and colleagues extended this to gastrocnemius crush injury — reduced hematoma and edema, no post-injury leg contracture, and normalization of muscle-injury enzymes (creatine kinase, LDH, AST, ALT) ^[14].

The contemporary picture is well summarized in two 2025 reviews. Vasireddi and colleagues' systematic review of 36 studies (35 preclinical, 1 clinical) covering 1993 to June 2024 concluded that BPC-157 enhances growth-hormone-receptor expression and pathways involved in cell growth and angiogenesis while reducing inflammatory cytokines, with improved functional, structural, and biomechanical outcomes in rodent muscle, tendon, ligament, and bony injuries. Human research remains limited to small pilot studies: one knee-pain cohort reporting 87.5 percent improved, an interstitial cystitis study, and an intravenous safety study. The review explicitly recommends that off-label clinical use should not outpace the human evidence base ^[20]. A narrative review the same year framed the risk-benefit tradeoff explicitly around chronic angiogenic exposure and a plasma half-life under 30 minutes ^[21].

Component 04 — TB-500

TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ-OH, CAS 885340-08-9) corresponding to residues 17-23 of native thymosin beta-4 (TMSB4X). Molecular weight 889 Da. In the canonical KLOW vial it occupies 10 mg of the 80 mg total (12.5 percent).

The LKKTET motif at its core is the actin-binding sequence of native thymosin beta-4, the 43-amino-acid protein that sequesters monomeric G-actin in a 1:1 complex under physiological salt conditions. Cassimeris and colleagues established this stoichiometry in 1992 in rabbit skeletal muscle and human platelet actin ^[15].

The critical caveat for any TB-500 monograph is that nearly all published mechanistic and animal-efficacy data attributed to 'thymosin beta-4' was generated with the full 43-amino-acid protein, not the seven-amino-acid TB-500 fragment marketed under that name. With that flag in place, the underlying Tβ4 literature includes: 42-61 percent acceleration of re-epithelialization in 8 mm full-thickness rat punch wounds at 5 μg topical or intraperitoneal ^[16]; accelerated corneal re-epithelialization with reduced IL-1β, KC, and MIP-2 mRNA after alkali burn in mice ^[17]; PINCH-Tβ4-ILK complex formation activating Akt with improved post-infarction cardiac function in mice ^[18]; and adult epicardial progenitor mobilization with neovascularization in the injured adult heart ^[19]. The cardiac, ocular, and progenitor-mobilization activities have been reported with full-length Tβ4. Fragment-level activity for the TB-500 heptapeptide has been demonstrated in some dermal wound paradigms but not most of the others. Marketing language across the research-peptide industry routinely conflates the two molecules.

Combination evidence — explicit

No controlled in-vivo study has tested the four-peptide KLOW blend against monotherapy of any single component, against any pairwise or three-peptide subset, or against placebo. The published synergy claims are mechanistic extrapolations from single-agent literature, not experimental findings on the blend.

The mechanistic rationale advanced for combination is that the four components target non-overlapping pathways: extracellular-matrix gene programs (GHK-Cu) ^[7], vascular and connective-tissue signaling (BPC-157) ^{[12][13][14][20]}, cytoskeletal remodeling and re-epithelialization (TB-500, anchored in Tβ4 data) ^[15][16], and innate-immune resolution (KPV) ^[1][2][3]. That rationale predicts additive activity if the blend is administered in a paradigm where all four pathways are limiting. Whether it actually produces additive or synergistic effects in any specific tissue or any specific injury model has not been tested.

The sensible read of the literature is that KLOW is, today, a research co-formulation built on the union of four single-agent literatures. The blend itself is an extrapolation.